CME vs Tradeweb Markets
CME and TW side by side, both in security & commodity brokers, dealers, exchanges & services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CME and TW compare
CME is the larger company, worth 3.7 times as much as Tradeweb Markets ($114B against $30.8B).
On earnings, CME is cheaper: it trades at 26.1× trailing earnings, against 31.2× for Tradeweb Markets.
Tradeweb Markets grew revenue faster over the last twelve months (14.4% versus 9.0% for CME).
Both pay dividends: CME yields 3.6% and Tradeweb Markets 0.41%.
Tradeweb Markets scores higher on the StockData Score (16 against 9 for CME), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CME | TW |
|---|---|---|
| Size and price | ||
| Market cap | $114B | $30.8B |
| Share price | $317.97 | $132.74 |
| Change, 1 year | 13.7% | 20.8% |
| Change, 5 years | 42.4% | 35.6% |
| Beta (5Y) | 0.36 | 0.65 |
| Employees | 3,875 | 1,569 |
| StockData Score | ||
| Total score | 9 | 16 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 1 | 3 (better) |
| Performance score | 2 | 4 (better) |
| Health score | 5 | 5 |
| Dividend score | 1 | 2 (better) |
| Valuation | ||
| P/E | 26.1× (better) | 31.2× |
| P/S | 16.3× | 13.5× (better) |
| P/B | 4.3× (better) | 4.7× |
| EV/EBITDA | 24.4× | 23.5× (better) |
| P/FCF | 26.3× (better) | 26.7× |
| PEG | 1.78 | 0.85 (better) |
| FCF yield | 3.8% (better) | 3.7% |
| Fair value | $262.19 | $132.68 |
| Margin of safety | −21.3% | −0.04% (better) |
| Growth | ||
| Revenue growth (TTM) | 9.0% | 14.4% (better) |
| Revenue growth, 5Y average | 6.0% | 18.1% (better) |
| Net income growth (TTM) | – | 44.3% |
| EPS growth (TTM) | 18.1% | 45.9% (better) |
| EPS growth, 5Y average | 13.7% | 33.8% (better) |
| Profitability | ||
| Operating margin | 65.7% (better) | 44.1% |
| Net margin | – | 39.8% |
| FCF margin | 62.1% (better) | 50.6% |
| Return on equity | – | 14.1% |
| Return on invested capital | 14.1% | 17.7% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | – | 490× |
| Current ratio | 1.02 | – |
| Altman Z-score | 0.59 | 17.82 (better) |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | 3.6% (better) | 0.41% |
| Years of dividend growth | 0 | 3 (better) |
| Dividend growth, 5Y average | −3.3% | 8.4% (better) |
| Buyback yield | – | 1.8% |
| Shareholder yield | 3.6% (better) | 2.2% |
| Ownership | ||
| Held by institutions | 90.0% | 50.4% |
| Held by insiders | 0.34% | 51.9% |
| Insider net buying, 12 months | −$33.6M (better) | −$46.9M |
| Superinvestors holding | 5 (better) | 2 |
| Short interest, % of float | 1.5% | 3.2% |
Go deeper
- CME stock overview
- CME income statement
- CME valuation and score
- TW stock overview
- TW income statement
- TW valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.